AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
AstraZeneca chief Pascal Soriot eyes record £28m pay bonanza
Pascal Soriot is already the highest-paid FTSE 100 chief executive, landing £17.7m last year at the Anglo-Swedish drugs giant.
www.thisismoney.co.uk
November 1, 2026 at 3:52 PM
AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
November 2, 2026 at 2:54 PM
AstraZeneca CEO eyes record £28m pay package bonanza, up from £17.7m.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
Previously, AstraZeneca CEO threatened to deny drugs to the NHS unless it paid more. Govt capitulated.
Blackmail works, delivers high rewards for shareholders and execs.
AstraZeneca profit jumps 23% as it unveils major savings plan
AstraZeneca profit jumps 23% as it unveils major savings plan
AstraZeneca's net profit jumped 23% in the third quarter on booming sales of its cancer drugs, as the British drugmaker unveiled a programme to save $1.5 billion (€1.34bn) a year to invest back into developing new medicines.
l.euronews.com
October 30, 2026 at 9:17 PM
AstraZeneca profit jumps 23% as it unveils major savings plan
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
The three-year restructuring programme will redirect savings into a pipeline of more than 180 projects as the drugmaker seeks to reach $80bn in annual revenue by 2030.
www.easterneye.biz
October 31, 2026 at 11:13 AM
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
AstraZeneca registra crescimento de 23% no lucro no 3º trimestre
AstraZeneca registra crescimento de 23% no lucro no 3º trimestre
A AstraZeneca reportou um aumento na receita e no lucro no terceiro trimestre, uma vez que as vendas expressivas de medicamentos oncológicos c...
valor.globo.com
October 30, 2026 at 1:09 PM
AstraZeneca registra crescimento de 23% no lucro no 3º trimestre
Battered by late-stage trial failures, AstraZeneca is following GSK with a push to save $1.5B a year.
AstraZeneca follows GSK with $1.5B annual savings push
AstraZeneca launches a restructuring to save $1.5B a year for R&D, beats Q3 sales forecasts and cuts several trials, including EMERALD-2.
endpoints.news
October 30, 2026 at 12:16 PM
Battered by late-stage trial failures, AstraZeneca is following GSK with a push to save $1.5B a year.
AstraZeneca says its reorg could mean R&D cuts and clinical trials shifted to emerging markets.
AstraZeneca says reorg could mean R&D cuts and trials shifted to emerging markets
AstraZeneca's CEO Pascal Soriot & CFO Aradhana Sarin outline restructuring: cuts near Farxiga/Brilinta, reinvesting $1.5B in oncology, cell therapy & AI.
endpoints.news
October 30, 2026 at 6:18 PM
AstraZeneca says its reorg could mean R&D cuts and clinical trials shifted to emerging markets.
Albemarle County is paving the way for a groundbreaking $4.5 billion AstraZeneca pharmaceutical facility that promises to bring 600 jobs and transform the local economy!
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
Board approves conveyance of 82.028 acres in Rivanna Futures to EDA to enable AstraZeneca project
Albemarle County approved a resolution to convey approximately 82.028 acres (Land Bay 82) to the county Economic Development Authority, enabling the EDA to provide incentives and convey property to AstraZeneca, a project staff said entails a $4.5 billion investment and about 600 jobs.
citizenportal.ai
November 2, 2026 at 8:07 AM
Albemarle County is paving the way for a groundbreaking $4.5 billion AstraZeneca pharmaceutical facility that promises to bring 600 jobs and transform the local economy!
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
Click to read more!
#AlbemarleCounty #VA #CitizenPortal #EconomicDevelopment #WorkforcePartnerships
The FTSE 100 pharmaceutical company said the three-year programme would deliver $1.5bn in annual benefits
AstraZeneca announces $2bn restructuring to invest in drugs pipeline
www.thetimes.com
October 30, 2026 at 9:18 AM
The FTSE 100 pharmaceutical company said the three-year programme would deliver $1.5bn in annual benefits
November 2, 2026 at 9:38 AM
November 2, 2026 at 9:28 AM
AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink | #biotechsky #pharma
AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink
Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual savings by 2029. | Facing looming patent cliffs, AstraZeneca has launched a...
www.fiercepharma.com
October 31, 2026 at 1:58 PM
AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink | #biotechsky #pharma
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
The three-year restructuring programme will redirect savings into a pipeline of more than 180 projects as the drugmaker seeks to reach $80bn in annual revenue by 2030.
www.easterneye.biz
October 31, 2026 at 11:30 AM
AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
#AstraZeneca #PharmaceuticalInnovation #HealthcareInvestment #RevenueGrowth #BiotechFuture
www.easterneye.biz/astrazeneca-...
AstraZeneca Plc $AZN Stock Sold by Choreo LLC
Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659…
Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659…
AstraZeneca Plc $AZN Stock Sold by Choreo LLC
Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659…
news-area.com
November 1, 2026 at 8:58 PM
AstraZeneca Plc $AZN Stock Sold by Choreo LLC
Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659…
Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659…
The payments by Merck, Eli Lilly, Novartis and AstraZeneca allegedly helped fund a corruption scheme that kept drug prices high and limited competition across Russia’s public healthcare system.
Western Pharma Giants Paid Millions to Russian Distributors Linked to Fraud, Whistleblower Report Says - The Moscow Times
Four major Western pharmaceutical companies paid tens of millions of dollars in unusually high bonuses to Russian middlemen to supply cancer drugs to state hospitals, according to whistleblower docume...
www.themoscowtimes.com
November 2, 2026 at 5:58 PM
The payments by Merck, Eli Lilly, Novartis and AstraZeneca allegedly helped fund a corruption scheme that kept drug prices high and limited competition across Russia’s public healthcare system.
🔘 BSC and AstraZeneca sign agreement to advance AI and supercomputing applied to healthcare.
➡️ bsc.es/4qZ
➡️ bsc.es/4qZ
October 29, 2026 at 10:46 AM
🔘 BSC and AstraZeneca sign agreement to advance AI and supercomputing applied to healthcare.
➡️ bsc.es/4qZ
➡️ bsc.es/4qZ
AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market. on.wsj.com/4smqBce
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market.
on.wsj.com
October 26, 2026 at 12:14 AM
AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market. on.wsj.com/4smqBce
ASTRAZENECA: 3Q CORE EPS $2.79, EST. $2.62
October 30, 2026 at 7:03 AM
ASTRAZENECA: 3Q CORE EPS $2.79, EST. $2.62
*ASTRAZENECA 3Q CORE EPS $2.79, EST. $2.62
October 30, 2026 at 7:03 AM
*ASTRAZENECA 3Q CORE EPS $2.79, EST. $2.62
🇲🇦 Le groupe pharmaceutique anglo-suédois AstraZeneca numérise Sanady, son programme marocain d’aide aux malades du cancer [Barlamane]
Le groupe pharmaceutique anglo-suédois AstraZeneca numérise Sanady, son programme marocain d’aide aux malades du cancer [Barlamane] - afropages.fr
Le laboratoire anglo-suédois AstraZeneca a officiellement rattaché, vendredi 30 octobre, le portail marocain Sanady à Cancer Care Africa, son programme continental de lutte contre le cancer, dans le r...
twp.ai
November 1, 2026 at 2:19 PM
🇲🇦 Le groupe pharmaceutique anglo-suédois AstraZeneca numérise Sanady, son programme marocain d’aide aux malades du cancer [Barlamane]
ICYMI: AstraZeneca bets $2B in cuts on its own drug pipeline #AstraZeneca #PharmaNews
AstraZeneca bets $2B in cuts on its own drug pipeline
AstraZeneca is restructuring to the tune of $2 billion in charges to unlock $1.5 billion in annual savings — all funneled back into developing new medicines. With late-stage trial setbacks weighing on its stock, the pharma giant is doubling down on its ambitious goal of $80 billion in revenue and 20 new drugs by 2030.
dlvr.it
October 31, 2026 at 12:24 PM
ICYMI: AstraZeneca bets $2B in cuts on its own drug pipeline #AstraZeneca #PharmaNews